Buy SPRO by Sep 13, 2026.

​ Anyone looking into Spero Therapeutics? Key indicators including test efficacy, regulatory reviews and financial investment - all seems promising. ​ **Clinical trial foundation and Regulatory:** ​ \- Overall success reached 58.5% for oral tebipenem HBr compared to 60.2% for the standard IV treatment and the drug was found to be statistically non-inferior to intravenous (IV). ​ \- In May 2025, an independent data monitoring committee recommended halting the trial early because tebipenem HBr rapidly and clearly met its primary …